Luminex Corp. (NASDAQ:LMNX)’s share price shot up 3.3% during mid-day trading on Wednesday . The stock traded as high as $21.03 and last traded at $20.98, with a volume of 124,673 shares trading hands. The stock had previously closed at $20.30.

Several research firms recently issued reports on LMNX. Piper Jaffray Cos. reaffirmed a “hold” rating and issued a $20.00 price objective (up from $19.00) on shares of Luminex Corp. in a research report on Tuesday, May 3rd. Leerink Swann reiterated a “hold” rating and set a $22.00 target price on shares of Luminex Corp. in a research note on Tuesday, May 3rd. Finally, Zacks Investment Research lowered shares of Luminex Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, April 14th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $20.83.

The company has a market capitalization of $923.14 million and a PE ratio of 23.93. The company has a 50 day moving average of $20.19 and a 200-day moving average of $19.71.

Luminex Corp. (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, May 2nd. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.15. The business had revenue of $63 million for the quarter, compared to analysts’ expectations of $60.98 million. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.23 earnings per share. Equities research analysts anticipate that Luminex Corp. will post $0.67 earnings per share for the current fiscal year.

Other large investors have recently made changes to their positions in the company. EQIS Capital Management increased its stake in shares of Luminex Corp. by 883.5% in the fourth quarter. EQIS Capital Management now owns 46,942 shares of the company’s stock valued at $1,004,000 after buying an additional 42,169 shares during the period. Russell Frank Co increased its stake in shares of Luminex Corp. by 47.1% in the fourth quarter. Russell Frank Co now owns 238,775 shares of the company’s stock valued at $5,167,000 after buying an additional 76,444 shares during the period. Nationwide Fund Advisors increased its stake in shares of Luminex Corp. by 259.4% in the fourth quarter. Nationwide Fund Advisors now owns 105,495 shares of the company’s stock valued at $2,257,000 after buying an additional 76,140 shares during the period. California State Teachers Retirement System increased its stake in shares of Luminex Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 79,760 shares of the company’s stock valued at $1,706,000 after buying an additional 1,282 shares during the period. Finally, American Century Companies Inc. increased its stake in shares of Luminex Corp. by 0.4% in the fourth quarter. American Century Companies Inc. now owns 160,075 shares of the company’s stock valued at $3,424,000 after buying an additional 705 shares during the period.

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.